Preliminary figures 2020 and forecast 2021
DFV Deutsche Familienversicherung AG FRANKFURT/MAIN | 21 January 2021
FREP (DPR)
German Financial Reporting Enforcement Panel (FREP)

- FREP has been commissioned by BaFin to conduct a sample audit of DFV's 2018 balance sheet.
- In addition to minor comments, a disagreement arose regarding the allocation of IPO costs.
- To avoid a protracted legal dispute, DFV agreed to FREP's findings.
IPO costs 2018 German Financial Reporting Enforcement Panel (FREP)
- According to IFRS, the costs of the IPO, which at DFV amounted to approximately € 3.6 million for the 2018 IPO, are to be allocated according to a reasonable formula if old and new shares are placed at the same time (IAS 32.38). The amount relating to the raising of new capital, i.e. the placement of new shares, is to be reported directly in equity, while the amount for making old shares tradable is to be reported as an expense.
- DFV conducted the IPO exclusively to acquire new capital. Old shares were not sold as part of the IPO, so the entire costs of the IPO were recognised directly in equity.
- FREP now explicitly denies this opinion for € 0.8 million (mainly employee shares), as there is no direct connection to the capital increase.
- For the remaining €2.8 million, it is noted that these were not allocated according to "meaningful codes" and that at least part of these costs should have been reported in the 2018 expenses. However, the FREP was unable to quantify this amount exactly. A breakdown by number of shares was not justifiable for us, as this would not have led to a causation-based breakdown.
- We would like to make it clear that these costs are already included in DFV's equity capital, so there is no change in DFV's asset situation or future results.
CareFlex Chemie
CareFlex Chemie
Background to the decision

In BaFin's view, extrapolation from past interest rates is not permissible for strongly growing insurance companies.
Alternative methods to the common ACIR method must have the same security (90%).
The interest rate achieved by DFV in 2020 is 2.5%. DFV
CareFlex Chemie
Background to the decision
On 17 December 2020, DFV was requested by BaFin to provide evidence that the actuarial interest rate of 2% can be provided with sufficient security. A deadline of 31 December 2020 was set for this. BaFin formulated a requirement for the proof to confirm 90% security.

On 22 December 2020, DFV submitted an ALM study confirming adequate security. Since BaFin had informed the consortium at the same time that it currently did not have the proof of sufficient security of an underwriter and both R+V and Barmenia could think that it could only be DFV, we were therefore forced to exit as the consortium members – incorrectly – feared an infection of the interest rate in future premium adjustments.
Performance of the DFV AG share
Share price from 28.12.2020 to today

The termination agreement between consortium members was signed on 30 December 2020 after close of trading.
Summary
The forced exit from CareFlex is frustrating and ultimately unfounded.
Despite CareFlex Chemie, we continued our regular insurance business in 2020 without any restrictions.

What we achieved in 2020
Above-average growth despite COVID-19
Preliminary key figures FY 2020 (IFRS)

- * Insurance industry 2020 as a total according to GDV industry data:
- Gross premiums written: € 220.1 bn (+1.2%)
- Policies: 448.6 million (+0.5%)
Source: https://www.gdv.de/de/themen/news/geschaeftsentwicklung-2020---zahlen-im-ueberblick-65316
Investing in our growth, profitable in our core business
Underwriting result according to IFRS
| In € million |
FY 2019 |
FY 2020 |
YOY change |
Gross premiums written |
90.2 |
114.6 |
+27% |
Net premiums written |
54.1 |
62.1 |
+15% |
Expenses for insurance claims (gross) |
-44.8 |
-69.0 |
+54% |
Expenses for insurance claims (net) |
-29.7 |
-35.7 |
+20% |
Underwriting result I (gross) |
45.4 |
45.6 |
0% |
Underwriting result I (net) |
24.4 |
26.4 |
+8% |
Costs (without sales expenses; gross) |
-17.3 |
-22.9 |
+32% |
Costs (without sales expenses; net) |
-10.2 |
-12.4 |
+21% |
Underwriting result II (gross) |
28.1 |
22.7 |
-19% |
Underwriting result II (net) |
14.2 |
14.1 |
-1% |
Sales expenses (gross) |
-37.5 |
-37.7 |
0% |
Sales expenses (net) |
-22.8 |
-24.8 |
+9% |
Underwriting result III (gross) |
-9.4 |
-15.0 |
+60% |
Underwriting result III (net) |
-8.6 |
-10.7 |
+25% |
Capital investments (after costs) |
+3.4 |
+0.8 |
-77% |
Underwriting result IV (net) |
-5.2 |
-9.95 |
+91% |
Further key figures FY 2020:
- Combined Ratio (gross): + 7.0 PP
- FY 2020: 109.6%
- FY 2019: 102.6%
- Claims ratio (net): + 2.6 PP
- FY 2020: 63.1%
- FY 2019: 60.5%
- Market value capital investments: + 14.3%
- FY 2020: € 140m
- FY 2019: € 122.5m
Note: The result may still change between +/- € 0.5 million.
The target value for the 2020 result was between € -9 and -11 million and has been achieved.
What we achieved in 2020
- Continuation of our classic insurance business, despite:
- CareFlex Chemie
- COVID-19 pandemic
- Two lockdowns
- Achievement of our targets with stable sales costs of 12 monthly premiums:
13
- ~ € 30 million new business
- Thanks to excellent technology and our employees, who are also committed to driving the business forward in their home offices.

Where we want to go
Our main targets for 2021:
-
-
- € 30 million new business
- Existing premiums of € 190 million
- Reduction of losses to € 4 million
- New markets
- New structures
- New insurance products
- More digitalisation
- New CFO

Our growth map 2021


Solid and guaranteed growth in our core business

- New P&C products
- New combined insurance products
New products New risk carriers New markets
P&C
Life

In coordination with BaFin, the application will be submitted in the first half of 2021

Market entry in Austria in the second quarter 2021
More digitalisation
One focus for further growth will be more digitalisation:
- More voice assistants
- More online communication
- More automation

More digitalisation: the future's insurance take out
Alexa, I want supplementary dental insurance!
In 2018, a skill was already programmed for digital product consulting that conducts a consulting dialogue and accesses the actuarial calculation core via an API interface.
We are convinced that the insurance take out of the future will also take place via digital voice assistants. That's why you can already take out DFV household, liability, dental and supplementary long-term care insurance via Amazon's Alexa.

More digitalisation: best customer portal – best Chatbot*
Customer-centricity at its best

More digitalisation: best app – free insurance take out
Simply the best for our customers


Also rated 4.9 stars in Google Play Store!
The ratings are comments from real users. They were translated into English for this presentation.
More digitalisation
Continuation of digitalisation in claims and benefits settlement
- Increasing dark processing rate in benefits settlement
- Increasing automation in claims settlement
- Expansion of artificial intelligence in claims and benefits settlement
- Completion of IT outsourcing
- System adjustments for expansion abroad
- Introduction of the combined insurance product

Result 2020
Result in € million

23
New CFO: Dr Karsten Paetzmann
New structure of the finance department
As of 1 February 2021, Dr Karsten Paetzmann will take over the CFO function from CEO Dr Stefan Knoll, who has been managing it on an interim base.
Career:
- Since 2012: Various positions at BDO
- Since 2018: Partner and Chair of Financial Services
- Since 2013: Head of Global Financial Advisory Corporate Finance
- Since 2012: Head of Financial Advisory
- Since 2015: Lecturer, Frankfurt School of Finance & Management

Guidance 2021
- + 100,000 new policies
- + € 30 million new business
- New products
- New risk carriers
- New markets
With a loss of only € 4 million*
*Without consideration of the reinsurance contract CareFlex Chemie

Outlook: continuation of profitable growth

Looking forward to your questions!

Dr Stefan M. Knoll CEO & CFO
Your contact:
Lutz Kiesewetter Head of IR & PR +49 (0)69 / 74 30 46 396 [email protected]
Our next IR dates:
| 18/03 |
Annual Press Conference on the 2020 financial report |
| 24/03 |
Metzler Micro Cap Days |
| 12/05 |
Q1 results 2020 |
| 19/05 |
Annual General Meeting |
| 21/05 |
German SMID Cap One-on-One Forum |
